摘要
目的近年来,随着靶向药物在抗肿瘤治疗中应用,其引起的肝损伤也备受人们关注。本研究探讨安罗替尼治疗晚期肿瘤患者肝功能异常的发生率、临床特点及预后。方法选取2018-06-01-2019-07-31广饶县人民医院使用安罗替尼治疗的123例晚期肿瘤患者为研究对象,对其年龄、临床表现、生化指标及预后进行分析。结果 123例患者,用药期间共15例(12.20%)发生肝功能异常。其中>60岁患者9例,占所有肝功能异常病例的60%。各类人群间肝损伤率差异无统计学意义,P>0.05。15例发生肝功能损伤的患者均表现为转氨酶不同程度的升高,其中5例伴有总胆红素异常,3例同时伴有上腹部不适、恶心、食欲差及乏力等症状。肝损伤发生时间在用药0~3个月的12例,占80.00%;>3个月的3例,占20.00%。所有肝损伤患者进行相应处理后均恢复,未出现不可逆的严重不良反应。1例患者因肝功能损伤而停药,其余14例均继续使用安罗替尼治疗。结论安罗替尼治疗晚期肿瘤患者应定期监测肝功能,观察患者症状,出现异常及时处理。
OBJECTIVE In recent years,with the application of targeted drugs in anti-tumor therapy,the liver damage caused by the targeted drugs has attracted much attention.The purpose of this study was to monitor the incidence,clinical features and prognosis of liver dysfunction during the treatment of anlotinib.METHODS To collect the hospitalized patients in people’s hospital of guangrao since June 1,2018 to July 31,2019 including the age,clinical manifestation,laboratory biochemical indicators and prognosis.RESULTS A total of 123 cases were recorded in this study,and 15 cases(12.20%)had abnormal liver function during the medication.Among the 15 patients,9 cases(60.00%)were older than 60 years old.There was no significant difference in the rate of liver damage among different groups of people.All 15 patients showed elevated levels of transaminases.Among them,5 cases were associated with abnormal bilirubin,and 3 cases were accompanied by symptoms of upper abdominal discomfort,nausea,poor appetite and fatigue.12 cases(80.00%)of liver function abnormalities occurred in the first 3 months of administration,and 3 case(20.00%)occurred after 3 months.The prognosis of all patients with hepatic impairment was acceptable,and they all recovered after corresponding treatment.One patient discontinued due to liver damage,and the remaining 14 patients continued to be treated with anlotinib.CONCLUSION Liver function should be monitored regularly during the use of anlotinib,and the patient’s symptoms should be closely observed.
作者
马海明
张海波
任燕
李莉
MA Hai-ming;ZHANG Hai-bo;REN Yan;LI Li(The People’s Hospital of Guangrao,Dongying 257300,P.R.China)
出处
《社区医学杂志》
2020年第12期872-875,共4页
Journal Of Community Medicine
基金
中华国际医学交流基金会资助(Z-2018-32-180052)。
关键词
安罗替尼
分子靶向药物
肝损伤
预后
anlotinib
molecular targeted drug
liver damage
prognosis
